The Medicines — Medicines — Investor Presentation (November 2010)
29 slides from The Medicines's investor presentation, Nov 22, 2010
Slide 1: The Medicines Company Investor Update November 2010
THE MEDICINES COMPANY Investor Update November 2010
Slide 2: Safe harbor: Forward looking statements
Safe harbor Forward looking statements Statements contained in these slides about The Medicines Company (the "Company"), the Company's projected revenues and financial results, the Company's products and product candidates, and the timing of clinical trial results, regulatory submissions, product or
Slide 3: Acute / intensive care hospital medicine
Acute | intensive care hospital medicine Expanding acute episodes, concentration of care facilities, rising demand worldwide
Slide 4: Acute / intensive care hospital medicine is an attractive market
Acute | intensive care hospital medicine is an attractive market Expanding global acute episodes, concentration of care facilities, rising demand Ischemic heart disease (#1), stroke (#2), and serious hospital infections (~#10) will remain among the leading causes of death, morbidity and hospital cos
Slide 5: Unique time to invest in MDCO
Unique time to invest in MDCO Opportunity to participate in growth of acute | intensive care hospital medicine worldwide 1. Established | expanding | presence Angiomax(r) (bivalirudin) a growing $400M+ franchise in acute hospital arterial anticoagulation 45% CAGR since launch - >3 million PCI patien
Slide 6: MDCO established and expanding presence in acute / intensive hospital medicine
MDCO | established | expanding | presence in acute | intensive hospital medicine Focused business plan | Angiomax $400M+ franchise | continued growth anticipated 1.
Slide 7: MDCO established and expanding: purpose, vision, mission, goals
MDCO | established | expanding Our purpose Vision | where we are going We provide leading solutions for leading hospitals Biopharmaceuticals | knowledge | hospital customers | world-class medical | economic | results | acute | intensive care Mission | how we plan to get there Required capabilities F
Slide 8: Angiomax is the growing US market leader in PCI
MDCO | established | expanding Angiomax is the growing US market leader in percutaneous coronary intervention (PCI) Net revenue: 45% CAGR 2001-9 Volume has driven recent revenue growth Extensive clinical program in PCI Four major randomized trials from SA to STEMI Comparative effectiveness studies E
Slide 9: Continuing to build the Angiomax franchise worldwide
MDCO | established | expanding Continuing to build the Angiomax franchise worldwide Potential sources of growth: US volume & pricing EU volume growth 40% + p.a. Expanding geography Eastern Europe, Turkey, Russia India Brazil Exploratory work in China Immediate drivers Potential sources of growth: St
Slide 10: Cleviprex is being set up for re-launch in US
MDCO | established | expanding Cleviprex is being set up for re-launch in US and approval in Germany | UK | Australia Strong formulary adoption during 1st launch year Cleviprex was approved by FDA in 3Q 2008 with a broad label for the treatment of blood pressure when oral agents are not feasible or
Slide 11: Re-launch Cleviprex in US, launch in rest of world
MDCO | established | expanding Re-launch Cleviprex in US, launch in rest of world Secure high quality supply chain Hospira currently making validation batches for US release Anticipate drug availability 1H 2011 Resume ex-US regulatory process Immediate drivers Refocus brand on neurocritical care Int
Slide 12: Development portfolio value: six products/compounds in addition to Angiomax
Development | portfolio | value Six products | compounds in addition to Angiomax - a series of major value-drivers expected 2.
Slide 13: Six products/compounds in addition to Angiomax: major value-drivers expected
Development | portfolio | value Six products | compounds in addition to Angiomax - a series of major value-drivers expected Acute | intensive care products and compounds Anticipated major milestones 2010-2013 Start of CHAMPION PHOENIX phase III trial Start of SOLO phase III trials Start of MDCO-2010
Slide 14: Cangrelor: Phase III iv platelet P2Y12 inhibitor for PCI and ACS
Development | portfolio | value Cangrelor: Phase III iv platelet P2Y12 inhibitor for PCI and ACS Acute anti-platelet profile Rapid and titrateable onset of action Complete platelet inhibition Recovery of platelet function in 1 hour Clinical effect and safety demonstrated Significant 45% reduction in
Slide 15: Cangrelor: development program considerations
Development | portfolio | value Cangrelor: Phase III iv platelet P2Y12 inhibitor for PCI and ACS Development program considerations CHAMPION PHOENIX phase III in a PCI population Lessons from the large CHAMPION dataset Universal MI definition No P2Y12 inhibitor prior to randomization Add ARC-defined
Slide 16: Oritavancin: Phase III iv antibiotic for gram-positive infections
Development | portfolio | value Oritavancin: Phase III iv antibiotic for serious gram-positive infections including MRSA Microbiological profile Rapid bactericidal action Active against clostridium difficile including spores Potential single dose iv treatment to cure MRSA Potentially reduced hospita
Slide 17: Oritavancin: SOLO-1 and SOLO-2 trial design
Development | portfolio | value Oritavancin: Phase III iv antibiotic for serious gram-positive infections including MRSA Multicenter, double-blind, randomized Single-dose iv oritavancin vs. vancomycin 7-10 days Non-inferiority for the primary efficacy outcome Cessation of spread or reduction in size
Slide 18: MDCO-2010: Phase II iv antifibrinolytic to reduce surgical blood loss
Development | portfolio | value MDCO-2010: Phase II iv antifibrinolytic to reduce surgical blood loss Targets fibrinolysis and coagulation Primary: plasmin | plasma kallikrein Secondary: factor X | factor XI | aPC Small molecule Liquid ready-to-use formulation Preclinical data, potential to overcome
Slide 19: MDCO-216: Phase 0-I reverse cholesterol transport agent
Development | portfolio | value MDCO-216: Phase 0-I genetic variant reverse cholesterol transport agent HDL-C is a potent inverse CV risk factor HDL apo A-I is anti-atherosclerotic in animals Human carriers of variant apo A-I Milano Have low levels of HDL-C (0.25-0.78 mmol/L), yet Enjoy less atheros
Slide 20: MDCO-216: renewed interest in HDL
Development | portfolio | value MDCO-216: Phase 0-I genetic variant reverse cholesterol transport agent CSL-112 (Reconstituted HDL) - CSL ApoA-I Milano/Phospholipid Complex - SemBioSys ATI-5261 - Artery Therapeutics / Roche 5-Ala - NIH / KineMed Cerenis HDL - Cerenis Therapeutics Trimeric A-I - Bore
Slide 21: Leadership, development know-how, commercial focus
Leadership | development know-how | commercial focus Hospital market knowledge | relationships | record of innovation 3.
Slide 22: MDCO senior leadership
Know-how | capabilities | depth MDCO senior leadership MDCO has considerable strength, depth and breadth of leadership and continues to build professional competences All five of the founders of the firm has either stayed with MDCO or have returned after periods working in other entities The group h
Slide 23: We design, perform and report influential clinical trials
Leadership | development know-how | commercial focus We design, perform and report influential clinical trials Trial name Design Patients Principle publication(s) Guidelines Label REPLACE-2 Angiomax vs. heparin + GPIIb/IIIa in planned PCI ~6,000 JAMA Lancet Yes US | EU ACUITY Angiomax vs. heparin +
Slide 24: We concentrate on <3,000 hospitals worldwide
Leadership | development know-how | commercial focus We concentrate on <3,000 hospitals worldwide More than 80% of acute cardiac care, including PCI, is performed in 2,548 leading hospitals in 26 countries across 14 language zones. These institutions represent our call list. We have mapped their whe
Slide 25: Disciplined financial focus
Disciplined | financial | focus Strong foundations and planned sustainable growth 4.
Slide 26: Strong foundations and planned sustainable growth
Disciplined | financial | focus Strong foundations and planned sustainable growth Total net revenue ($M) Cash flow from operations ($M) Generated cash flow ~$245M since 2006 Deal-making & YE cash ($M) Angiox EU Curacyte Angiomax lifecycle Argatroban Targanta MDCO-216 MDCO-2010 milestone 2010 3rd qua
Slide 27: New business ventures activities
Disciplined | financial | focus New business ventures activities We will continue to focus on acute | intensive care business development opportunities for leading hospitals Cardiovascular | stroke | serious infection Innovative products Low upfront payments Late stage - ideally with low R&D require
Slide 28: Our strategic approach to growth
Disciplined | financial | focus Our strategic approach to growth Net sales development We believe that Angiomax will continue to grow in US with extended exclusivity through mid 20151 as the results of a combination of volume expansion and price increases linked to the value our health and economic
Slide 29: Unique time to invest in MDCO
Unique time to invest in MDCO Opportunity to participate in growth of acute | intensive care hospital medicine worldwide 1. Established | expanding | presence Angiomax(r) (bivalirudin) a growing $400M+ franchise in acute hospital arterial anticoagulation 45% CAGR since launch - >3 million PCI patien